
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.
Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...





